Category Archives: Biotechnology

By Nicolas Chahine, InvestorPlace Contributor|Mar 28, 2017, 11:13 am EDT

It would seem that the toxicity that the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) were suffering on Wall Street is waning. Until recently, the political headlines were a threat to all healthcare and biotech stock holders.The thesis that biotech stocks are untouchable, however, is no longer the dark cloud that it was.

So can I buy the IBB long from here with confidence? Not in my opinion. I think that trading the IBB should fit into a bullish macro scenario, which we may no longer have. Equity markets are near all-time highs with few catalysts that are not yet priced in. Traders quickly priced in the fiscal spending and legislative advantage that President Trump promised. This week we saw the first promise die, so the onus is now on the bulls to prove they can deliver the rest.

Click to EnlargeSo to say the least, the perfectly bullish scenario has some rebuilding to do. This creates an opportunity to take a short-term bearish bet on the IBB. I can do this without spending any out-of-pocket money.

Before you label me a bear, I am merely shorting the near-term price action and not the fundamentals of any components within the IBB. In fact, I will leverage their value to pay for my bet.

The Trade: Buy the IBB June $280/$275 debit put spread for $1.30. This is a bearish trade that could triple my money if IBB falls through my spread before mid-June. The cost of entry is my maximum potential loss. I usually like to hedge my bets, and in this case, I will sell downside risk against the value of the IBB. The trick is to find proven support zones.

The Bank: Sell the IBB Jan $200 put and collect $3 per contract. The current 30% price buffer gives this leg a 90% theoretical chance of success. As long as IBB stock stays above my January sold strike, any premium I recover from selling the June debit put spread would be pure profit. Having no out-of-pocket risk makes managing this trade relatively easy.

Fair warning: Selling puts is risky, so only do it if you are willing and able to own the IBB shares at the strike price.

Nicolas Chahine is the managing director of SellSpreads.com. Learn options as easy as 1-2-3 here. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

Article printed from InvestorPlace Media, http://investorplace.com/2017/03/short-the-ishares-nasdaq-biotechnology-index-etf-ibb-etf/.

2017 InvestorPlace Media, LLC

Read the original here:
IShares Nasdaq Biotechnology Index: Short the Near-Term Action in ... - Investorplace.com

NEW YORK, March 27, 2017 /PRNewswire/ -- Use this report to:- Analyze existing and future agricultural biotechnology products and technologies that will be commercially important. - Receive a qualitative and quantitative description of the agricultural biotechnology industry. - Highlight key market and industry trends, as well as quantify the main market segments. - Receive information on agricultural biotechnologies, market applications, industry structure and competitive dynamics.

Highlights- The global market for agricultural biotechnology reached $29.2 billion in 2016. This market should reach $32.1 billion in 2017 and $53.7 billion in 2022, with a compound annual growth rate (CAGR) of 10.8%. - Genomic-enabled products as a segment reached $24.1 billion in 2016, and should reach nearly $26.5 billion in 2017 and $43.7 billion in 2022, with a CAGR of 10.6%.

STUDY GOALS AND OBJECTIVES BCC Research's goal for this study is to determine the specific applications and forecast global market demand for agricultural biotechnology products over a five-year period from 2017 through 2022. The main objective is to characterize and quantify the agricultural biotechnology products market by product type, geography, and purpose. In addition, the report analyzes the industry structure, competitors, strategic alliances, and intellectual property landscape. A total of 70 companies in the industry are profiled.

Agricultural biotechnology markets analyzed in this report include biotechnology tools, genomics enabled products, and biologicals. Biotechnology tools include DNA sequencing, biochips, RNA interference, synthetic biology, and genome editing. Genomics enabled products include biotech seeds and synthetic biology-enabled products. Biologicals include biopesticides, biostimulants, and genetic biologicals.

A key objective of the report is to provide a comprehensive analysis of the agricultural biotechnology industry, with an emphasis on products and technologies that are commercially important in the 2017 to 2022 time-period. Market segments with rapid growth rates are highlighted, as well as those segments with large market potential. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the agricultural industry.

The study will be particularly useful to those companies developing new genomics or proteomics technologies; discovering and development novel seed traits; doing plant breeding; interested in using novel biotechnologies in agriculture; or working inadvanced biotechnology fields like genome editing, synthetic biology, RNA interference, biochips, or DNA sequencing.

The study will also be useful to government agencies or institutions that are developing strategic initiatives for a country's agriculture policy and/or industry.

REASONS FOR DOING THE STUDY

Agriculture is a fundamental and strategic component for a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader.

The report does this by examining the main product applications and markets, helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments. The reader is thus able to better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, genome editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

INTENDED AUDIENCE

Read More

This study examines and analyzes existing and future agricultural biotechnology products and technologies that will be commercially important.

Markets are presented by product type, crop type, and geographical region. Important market segments covered include the main biotechnologies (DNA sequencing, biochips, RNA interference, synthetic biology tools, and genome editing tools) as well as synthetic biology-enabled chemicals and biofuels, biotech seeds, and biologicals.

In-depth coverage is provided for agricultural biotechnologies; growth driving forces; market applications; industry structure and competitive dynamics; companies and industry alliances; future market potential and product sales forecasts for the period 2017 through 2022. The report forecasts the future value of agricultural biotechnology products by product type and geography.

This report will be of particular interest to agriculture, chemicals, bio-energy, and biotechnology companies; as well as suppliers of genomics tools, synthetic biology, RNA interference, and DNA sequencing products. It will also be of interest to professionals within governments, think tanks, and regulatory agencies to understand the end uses of these technologies in agriculture.

SCOPE AND FORMAT

The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

BCC analyzes these technologies and products to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces.

BCC provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS, microarray companies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016.

70 agricultural and biotechnology companies are profiled in this report.

METHODOLOGY

BCC Research examined key users and producers in each of the enduser market segments and technology fields that will be commercially important during the next five years. Discussions with industry thought leaders, as well as secondary market research was performed.

Based on our analysis, we project the future applications of agricultural biotechnologies in the major enduser market segments and by technology type, and forecast sales revenues for 2017 through 2022.

INFORMATION SOURCES

BCC Research performed primary and secondary research for this report. Primary sources included key industry companies and leading research institutions. In addition, data were compiled from secondary sources, including company websites and industry, trade and government publications. Read the full report: http://www.reportlinker.com/p0958100-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agricultural-biotechnology-emerging-technologies-and-global-markets-300429907.html

Here is the original post:
Agricultural Biotechnology: Emerging Technologies and Global Markets - Yahoo Finance

OTTAWA, Ontario--(BUSINESS WIRE)--

Canada's biotech industry today welcomed the federal budget and its measures supporting the advancement of Canadian innovation in biotechnology centered sectors such as health/bio-sciences, clean technology and agri-food. Importantly the budget proposes support for the acceleration of innovation through the establishment of sector specific superclusters, including health/bio-sciences, agri-food and clean technology.

"The core of our industry is innovation - much of it coming out of universities. The Budgets focus on innovation and creating super clusters in biotechnology centered fields including health/bio-sciences, agri-food, and clean technology recognizes Canadas strengths in these areas and the enormous opportunity for the economy in successfully advancing biotechnology innovation. Today's commitments will result in products and therapies of the future and will accelerate the use of biotechnology in supporting the global competitiveness of Canadas traditional cornerstone economic sectors of agriculture, forestry, mining, energy and advanced manufacturing," commented Andrew Casey, President and CEO BIOTECanada.

Drawing on the nation's rich legacy of research, Canada now has an opportunity to become one of the worlds most successful modern biotech regions by transitioning its traditional industries into the new economy while drawing on its considerable strength of its investment in research. From universities, small mid-sized companies, hospitals and public research agencies across the country, Canadian biotech scientists make up the ecosystem ensuring Canadas biotechnology sector thrive.

Importantly, Canada already has in place many of the components necessary for global competitiveness and success in biotechnology. Indeed, Canada is home to a number of regional clusters which bring together: world-class universities and research institutes; biotech entrepreneurs; a significant multinational industry presence; and, a highly educated workforce. All told, the Canadian national biotech ecosystem is an economic strength that positions Canada well to compete in the emerging global bio-economy. The Budget will help harness many of these strengths to accelerate Canadas biotechnology innovation progress.

BIOTECanada looks forward to working with the federal government over the months ahead, offering a coordinated set of recommendations and mechanisms for the announced programs. Implementation consultations are key to ensuring the commitments realize the potential they offer to the biotechnology industry.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170322006371/en/

Read more from the original source:
BIOTECanada: Federal Budget Strengthens Biotechnology Industry Ecosystem Building Canadian Economy - Yahoo Finance

Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma ... The USA Commerce Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) dropped -2.02% to $38.90. During the trading on 03/27/2017, Company's stock ranged from $39.70 to ... Puma Biotechnology Inc (NASDAQ:PBYI) Broker Price Targets For ...Fiscal Standard Watch List: Puma Biotechnology Inc (NASDAQ:PBYI) , Red Rock ...NYSE Journal (press release) all 3 news articles »

Read this article:
Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma ... - The USA Commerce

Cellect Biotechnology Ltd (NASDAQ:APOP, TASE:APOP) shares shot up 74% in New York after it successfully performed the first stem cell transplant procedure on a cancer patient.

It happened in the group's phase I/II clinical trial in a blood cancer patient.

The stem cell firm's chief executive Dr Shai Yarkoni said: After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions.

"It is a first good step on a road that we hope will lead to stem cell based regenerative medicine becoming a safe commodity treatment at every hospital in the world.

Up to half of all stem cell transplant procedures, such as bone marrow transplants, result in life-threatening rejection disease, known as Graft-versus-Host-Disease (GvHD).

But the firm's ApoGraft technology aims to stop all that.

Now, the independent data and safety monitoring board (DSMB) has approved the enrolment of two further patients for the ApoGraft treatment to complete the first study cohort as planned.

Shares shot up 74% to reach $10.9 each.

Register here to be notified of future PROAC Company articles

Visit link:
First successful stem cell cancer transplant sees Cellect Biotechnology shares surge - Proactive Investors USA & Canada

Biotechnology Gets A Shot In the Arm Barron's The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump sectors including materials, industrials, and financials so far, suggesting that investors may be ... iShares Nasdaq Biotechnology (IBB) volatility low into Credit Suisse ...StreetInsider.com iShares NASDAQ Biotechnology Index (IBB) Rating Increased to ...BBNS all 5 news articles »

Go here to see the original:
Biotechnology Gets A Shot In the Arm - Barron's

What happened

Cellect Biotechnology (NASDAQ:APOP), an Israeli-based stem-cell company, today announced the first successful stem cell transplant procedure using its ApoGraft technology in a combined phase 1/2 clinical trial in a blood cancer patient, causing its shares to rise by as much as 115%. The company's stock has since cooled off, but is still up by 80% as of 3:00 p.m. EDT.

Image source: Getty Images.

Even though stem cell transplants can be a curative treatment for many blood disorders and blood-related cancers, they tend to be a treatment of last resort because of their life-threatening side effects, such as graft-versus-host disease (GvHD). So, if Cellect's ApoGraft technology turns out to be a viable workaround, it would be a major advancement in the field, and potentially an extremely lucrative product for the company.

While Cellect's announcement is indeed exciting, its stock still isn't a great long-term bet. Cellect exited 2016 with a paltry $8 million in cash andApoGraft is probably five to six years away from reaching the market. This current trial, after all, is simply a safety and proof-of-concept study that's not designed to provide a basis for a regulatory approval.

In addition, Bellicum Pharmaceuticals'adjunct T-cell therapy BPX-501 could reach the European market as one possible solution to the GvHD problem in blood cancer patients by early 2019, and in the U.S. by perhaps 2020. In other words, Bellicum has a significant head start on Cellect, which may diminish the commercial prospects ofApoGraft moving forward.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Continued here:
Why Cellect Biotechnology Stock Is Skyrocketing Today - Motley Fool

Agricultural biotechnologies are being applied to an increasing extent in crops, livestock, forestry, fisheries and aquaculture and agro-industries, to alleviate hunger and poverty, assist in adaptation to climate change and maintain the natural resource base.

They have not sufficiently benefited smallholder farmers and producers and consumers. More research and developmentof agricultural biotechnologies should be focused on the needs of smallholders.

In order to produce food in a sustainable way for an additional 2 billion people by 2050, a business-as-usual approach will not be sufficient.

This is especially true in the face of climate change and other forces threatening natural resources like biodiversity, land and water that are essential for food production and agriculture, including forestry and fisheries.

To meet these challenges, science and the application of biotechnologies as well as conventional technologies will play a key role.

FAO recognizes that when appropriately integrated with other technologies for the production of food, agricultural products and services, biotechnology can be of significant assistance in meeting the needs of an expanding and increasingly urbanized population. Regarding biotechnology, FAO assists its Member countries and their institutions by:

View original post here:
Biotechnology | FAO | Food and Agriculture Organization of ...

Biotechnology is a popular trend that can be found in various aspects of our everyday lives. While it is true biotechnology is a very complicated concept to grasp, it is also one of the most promising technologies to be found today. Biotechnology will help our society address some of its greatest challenges moving forward. Below are some very common use cases for biotechnology most people will have come in contact with already.

It is anything but surprising to learn biotechnology has made a big impact on the medical sector over the past few years. Biotechnology, or more specifically, bio-processing, is used to develop new pharmaceuticals which are often difficult to produce due to purity quality control requirements. Some of the more popular biotech pharmaceuticals include Remicade, Rituxan, Prevarn, and Avastin.

Very few consumers give fabrics a second thought, other than to determine whether the material would rub against the skin. Interestingly enough, most fabrics are dyed through a fermentation vat process. Biochemicals are very common in the production of dyes, polyester, and nylon. It is evident there is some form of biotechnology involved in every piece of synthetic clothing we wear today.

Even though biofuel is not as popular as it could be, the concept holds a lot of merit for the future. Biodiesel helps reduce the carbon impact, which is of great importance to the future of our species. To produce biofuel, one needs specific plant-derived sugars which are then fermented using biotechnology to create ethanol. Further advances in the development of biofuel will see the introducing of alternative compoundsto jet fuel.

It may come as a surprise to find out Goodyear Tire is actively exploring the boundaries of biotechnology. Through a partnership with Genencor, the company is researching synthetic rubber created out of mostly renewable raw materials. In doing so, the company hopes to replace the crude oil requirements necessary to produce a single passenger tie.

As unusual as it may sound, some of the foods we consume on a regular basis are a direct result of biotechnology. Most of the products usedin food and [soft] drinks are processed using biochemicals. Sweeteners, flavors and acidity regulators found in nearly every product are just a few examples of how biotechnology is affecting our daily lives. Even the packaging used by supermarkets is made of biochemicals.

It appears very few people are aware of what can be found in alcoholic beverages these days. The production process of alcohol is a clear example of industrial biotechnology. This process involves converting starch to sugar and fermenting the yeast. Both parts are biotechnology in its simplest form. There is a lot more to the beer in a bottle than meets the eye, that much is certain.

If you liked this article, follow us on Twitter @themerklenews and make sure to subscribe to our newsletter to receive the latest bitcoin, cryptocurrency, and technology news.

Read the original here:
Top 6 Everyday Products Using Biotechnology - The Merkle

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Changes in Registrant's Certifying Accountant Market Exclusive Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over ...

The rest is here:
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Changes in Registrant's Certifying Accountant - Market Exclusive